# Case EkcALOwaSilEJii11717 — Questions

#### **Case Details**

Demographics 61-year-old white female; food service manager

Chief complaint loss of vision

History of present illness

Secondary complaints/symptoms none

Patient ocular history last eye exam 5 years ago; amblyopia OS; wears PALs full time

Family ocular history father: retinal detachment

Patient medical history type II diabetes; last HbA1c: 8.7% (last month), FBS: 205 mg/dL (this morning), depression

Medications taken by patient Glucophage® Avandia®, Glucotrol®, Wellbutrin®

Patient allergy history NKDA

Family medical history father: type II diabetes

**Review of systems Mental status** 

Clinical findings

Habitual spectacle Rx

Pupils: PERRL, negative APD EOMs: full, no restrictions OU

Confrontation fields: full to finger counting OD, OS

Slit lamp

IOPs: OD: 15 mmHq, OS: 13 mmHq @ 1:30 pm by Goldmann applanation tonometry

**Fundus OD Fundus OS** 

Blood pressure: 127/82 mmHg, right arm, sitting

Pulse: 78 bpm, regular

· Character/signs/symptoms: suddenly can't see out of the right eye

· Location: OD · Severity: severe

Nature of onset: acute

Duration: 4 hours; noticed when she woke up this morning

Frequency: constant

· Exacerbations/remissions: none

 Relationship to activity or function: none · Accompanying signs/symptoms: none

Constitutional/general health: denies

· Ear/nose/throat: denies · Cardiovascular: denies

· Pulmonary: denies

• Dermatological: denies

Gastrointestinal: denies

· Genitourinary: denies

Musculoskeletal: denies

· Neuropsychiatric: denies

· Endocrine: denies

Hematologic: denies

· Immunologic: denies

• Orientation: oriented to time, place, and person

Mood: appropriate

· Affect: appropriate

 OD: +1.00 -0.50 x 080 add: +2.25; VA distance: CF @ 5 feet (PHNI) OS: +5.25 -0.75 x 095 add: +2.25; VA distance: 20/400 (PHNI)

lids/lashes/adnexa: 1+ MGD OD, OS

· conjunctiva: normal OD, OS

• cornea: clear OD, OS

· anterior chamber: deep and quiet OD, OS

iris: normal OD. OS

· lens: clear OD, OS

vitreous: see image 1 OD, posterior vitreous detachment OS

C/D: see image 1

macula: see image 1

• posterior pole: see image 1

• periphery: unremarkable

C/D: 0.25 H/0.25 V

- macula: normal
- posterior pole: several dot/blot hermes along arcades
- periphery: unremarkable



## Question 1/5

What is the MOST appropriate diagnosis of the patient's right eye condition observed in image 1?

- A) Preretinal hemorrhage
- B) Vitreous hemorrhage
- C) Ocular ischemic syndrome
- D) Valsalva retinopathy
- E) Central retinal vein occlusion
- F) Malignant hypertension

## Question 2 / 5

Which 3 of the following are known as "high-risk" characteristics for patients with this retinal diagnosis? (Select 3)

- A) Any degree of neovascularization of the optic disc (NVD) with an associated pre-retinal or vitreous hemorrhage
- B) Neovascularization elsewhere (NVE) with a size greater than 1/2 of the disc area when associated with a pre-retinal or vitreous hemorrhage
- C) Neovascularization within 1 disc diameter of the optic disc (NVD) with a size greater than 1/4 to 1/3 of the disc area
- D) Any retinal edema within 500 microns of the center of the fovea
- E) Retinal edema greater than 1 disc area in size and within 1 disc diameter of the center of the fovea
- F) At least one quadrant of intraretinal microvascular abnormalities (IRMA)

#### Question 3 / 5

Which of the following systemic conditions can cause a falsely low measurement of a patient's hemoglobin A1c level?

- A) Chronic opioid use
- B) Iron deficient anemia
- C) Hyperbilirubinemia
- D) Pregnancy
- E) Alcoholism

#### Question 4 / 5

Which of the following is the BEST initial treatment option for this patient, considering her diagnosis and history of amblyopia?

- A) Monitor the condition for resolution
- B) Pars plana vitrectomy
- C) Panretinal photocoagulation
- D) Intravitreal injection of Vitrase®
- E) Intravitreal injection of Avastin®

## Question 5 / 5

Which of the following classes of medication does Glucophage® belong to?

- A) Sulfonylureas
- B) Alpha-glucosidase inhibitors
- C) Meglitinides
- D) Biguanides
- E) Thiazolidinediones